Pharmaceuticals

News Hour: Beximco Pharmaceuticals Limited (BPL) started the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada. The BPL today made the announcement following the approval of...

News Hour: Novo Nordisk announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycemia (low blood sugar levels) are at greater risk of...

News Hour: Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar and post-meal sugar control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study...

News Hour: Chilean healthcare company Banmedica SA told local regulators late on Friday that it had signed a non-binding agreement to sell all its shares to U.S.-based UnitedHealth Group Inc. “If the transaction...

News Hour: Two AstraZeneca drugs tackling lung cancer in different ways delivered impressive clinical results on Saturday, helping the British group offset July’s big clinical trial setback in the disease. Particularly notable was...

News Hour: The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc’s drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). The drug was cleared to treat adults with newly...

News Hour: The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes...

News Hour: Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging...

News Hour: Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack...

News Hour: Novartis is taking aim at drug-resistant malaria – a growing global problem – by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa...